Choose the nasal spray for seconds-long PT-141 administration or the mini troche for one compact oral-dissolve step. Rebody's bremelanotide family includes two nasal concentrations and two troche strengths, all refrigerated and built for as-needed intimacy routines.
The short answer
PT-141 is another name used for bremelanotide, a melanocortin-receptor agonist developed around sexual desire and arousal. FDA-approved Vyleesi contains bremelanotide as a 1.75 mg subcutaneous injection for acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Rebody's nasal sprays and troches are different finished products and routes. The spray bottle wins on seconds-long administration; the troche wins on a compact oral-dissolve routine. The phase 3 results used Vyleesi injection, while each Rebody format keeps its own dose and timing.
Available formats at a glance
| Format | Strengths | Package | Storage | Final dose instructions |
|---|---|---|---|---|
| Nasal spray | 5 mg/mL | 5 mL bottle | Refrigerated | Patient-specific prescription |
| Mini troche | 1 mg and 2 mg | 8 troches | Refrigerated | Patient-specific prescription |
Your prescription and dispensing label provide the pump output, sprays per use, priming, troche placement, timing, package duration, and refill cadence.
PT-141, bremelanotide, and Vyleesi
PT-141 is the development name commonly used for bremelanotide. Vyleesi is a specific FDA-approved bremelanotide injection with its own autoinjector, label, indication, dose, pharmacokinetics, and safety information.
A compounded nasal bottle or troche is not generic Vyleesi. It changes route, formulation, package, and exposure. The active ingredient is bremelanotide; Vyleesi refers to the branded injection, not every bremelanotide format.
This distinction prevents two common errors: calling any PT-141 product FDA-approved and quoting the injection's human outcomes as proof for a spray or troche.
What bremelanotide does
Bremelanotide activates melanocortin receptors in the central nervous system. Its sexual-health research centers on desire and distress rather than simply increasing genital blood flow.
That makes it different from sildenafil and tadalafil, which act through the nitric-oxide/cGMP blood-flow pathway used in erectile function. Desire and erection can interact, but they are not the same problem.
The strongest evidence is specific and useful: in premenopausal women with acquired, generalized HSDD, bremelanotide improved desire and reduced distress. Orgasm, lubrication, erection, relationship outcomes, and hormone replacement are different treatment questions.
What the injection trials measured
The two RECONNECT phase 3 trials randomized 1,267 premenopausal women with acquired, generalized HSDD. Participants used 1.75 mg subcutaneous bremelanotide as needed for 24 weeks.
The co-primary outcomes measured sexual desire and distress related to low desire. Bremelanotide improved both versus placebo. The number of satisfying sexual events did not improve significantly as a co-primary efficacy result.
That study population and route define the evidence. It is strong support for bremelanotide as a desire medication in that population, not a route conversion for Rebody's needle-free products.
What intranasal studies measured
A small double-blind crossover experiment studied one 20 mg intranasal dose in 18 premenopausal women with female sexual arousal disorder. It explored physiological and subjective arousal measures. It did not test either Rebody concentration or establish a retail pump dose.
Early intranasal research also included healthy men and men with mild-to-moderate erectile dysfunction. These small studies examined pharmacology and erectile response, not a modern pivotal indication or the finished 5 mL bottle.
Intranasal research therefore makes the route scientifically real. It does not authorize a precise onset claim, outcome percentage, or sprays-per-dose instruction.
Why the nasal bottle wins on simplicity
A metered spray can be administered in seconds and does not require waiting for a solid to dissolve. The 5 mL bottle is compact and familiar. For someone comfortable with nasal products, those are decisive practical advantages.
The dispensing label provides pump output, amount per actuation, priming, nostril technique, timing, and maximum frequency. Concentration alone cannot answer “how many sprays.”
Congestion, irritation, leakage, a blocked pump, or dislike of nasal sensation can erase the convenience. That is where troche becomes the better practical form.
Why troches remain a real alternative
The mini troche dissolves under the tongue or between gum and cheek. It avoids nasal administration and pump technique. Each package contains 8 troches at either 1 mg or 2 mg.
Troche use introduces different questions: dissolve time, saliva, taste, accidental swallowing, food and drink, mouth irritation, and the amount absorbed through mucosa. No route-specific clinical outcome study establishes the Rebody troche.
Choose troche for route preference, not because the lower printed milligram number implies gentler or more precise exposure.
Strengths cannot be converted across routes
Five or ten milligrams per milliliter describes concentration in a bottle. One or two milligrams describes active in one troche. The nasal amount per actuation remains unknown, and troche bioavailability is not established.
Do not convert a Vyleesi 1.75 mg injection into sprays or troches. Subcutaneous bioavailability and systemic exposure are route-specific. The same active name is not a conversion factor.
Only the final prescription can define the strength, amount, timing, and maximum use for each product.
Timing and spontaneity
People search PT-141 because they want an as-needed product that does not turn intimacy into a rigid daily medication schedule. That desire makes timing central.
The approved injection label says use at least 45 minutes before anticipated sexual activity, but that instruction belongs to Vyleesi injection. It cannot be copied onto a nasal bottle or troche. Small studies and online anecdotes report widely varying timing.
Both are prescribed as as-needed formats. Exact lead time comes from the instructions for the selected product.
Refrigeration and travel
Both formats are refrigerated. Keep the bottle or troche package labeled, protect it from freezing, and follow its temperature-excursion instructions during travel.
The nasal bottle needs leak protection and a cap. Troches need protection from heat, moisture, and physical damage. Do not decant either into an unlabeled travel container.
If a shipment arrives warm, record delivery timing and package condition. If a spray leaks or troches soften, crack, or become wet, check the product before use.
Safety follows the active and the route
The Vyleesi label contraindicates uncontrolled hypertension and known cardiovascular disease. It addresses transient blood-pressure increases, heart-rate reduction, nausea, focal hyperpigmentation, pregnancy, delayed gastric emptying, and reduced exposure to oral naltrexone.
Those injection-label facts define important bremelanotide questions. They do not prove that route-specific frequency or adverse-event rates are identical for a spray or troche.
Seek urgent help for severe allergic symptoms, chest pain, fainting, severe or persistent blood-pressure symptoms, or prolonged painful erection. Follow the route-specific instructions and escalation guidance supplied with the prescription.
Price, supply, and availability
Rebody's 5 mL nasal bottle is $99.50 first month, then $199. The 8-count troche package is $54.50 first month, then $109 for 1 mg, or $59.50 first month, then $119 for 2 mg. Billable days of supply remain prescription-specific. Eight troches do not automatically equal eight days or one month; a 5 mL bottle does not reveal its number of doses without metered output and prescribed sprays.
Both product families are available: $99.50 first month, then $199 per 5 mL nasal bottle; $54.50 first month, then $109 per 8-count 1 mg troche package; and $59.50 first month, then $119 per 8-count 2 mg troche package. Strength is prescribed within each route.
Compare package price, expected number of prescribed uses, cold shipping, and refill timing.
Questions people ask
Is PT-141 the same as bremelanotide?
Yes, PT-141 is a common development name for bremelanotide. Vyleesi is the specific approved injection product.
Which needle-free format is fastest?
Nasal administration takes less physical time. A clinical onset winner has not been established for the products.
Does PT-141 work for men?
Small early intranasal studies examined men, but Vyleesi is approved for premenopausal women with acquired, generalized HSDD, not male ED.
How long does it last?
Do not copy the injection or anecdotal timeline onto spray or troche. Final route-specific guidance should answer timing.
Can it be used with Viagra or Cialis?
That combination requires individualized safety instructions. Small research interest does not create a public stacking protocol.
Bottom line
Nasal PT-141 wins for seconds-long physical administration. The mini troche wins for a compact oral-dissolve routine without a pump. Both refrigerated formats make centrally acting bremelanotide available in a needle-free, as-needed form; patient-specific directions determine timing and supply.
Shop the formats and read the route guide
- See PT-141 nasal spray strengths
- See PT-141 mini troche strengths
- Read PT-141 nasal spray vs troche
- See the PT-141 nasal spray product
- See the PT-141 troche product
Primary sources
- FDA. Vyleesi prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210557s002lbl.pdf
- Kingsberg SA, Clayton AH, Portman D, et al. RECONNECT phase 3 trials. https://pubmed.ncbi.nlm.nih.gov/31599840/
- Diamond LE, Earle DC, Rosen RC, et al. Intranasal crossover experiment in 18 premenopausal women. https://pubmed.ncbi.nlm.nih.gov/16839319/
- Rosen RC and colleagues. Intranasal PT-141 in healthy men and men with mild-to-moderate ED. https://pubmed.ncbi.nlm.nih.gov/14963471/